Explore opportunities

Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.

Loading filters…

Tier Aip_iaip_neonatal
IAIP biologics & rapid LFIA for sepsis/NEC/HIE

Dual-path NICU play—IAIP biologic plus rapid LFIA on active SBIR stack.

~$3.7M+ active SBIR—physician-founder equity; Series A $5–10M band vs Inotrem/MeMed.

Entity: ProThera BiologicsPatents: 4Stage: sbir clinical enabling
US7932365B2US9572872B2USRE47972E1US20070297982A1R44AI141283R44NS084575
Open dossier
Tier Aip_monaghan_deep_rna_dx
Deep RNA transcriptomic ICU diagnostics (host + pathogen)

One blood draw, full transcriptome—faster pathogen ID than culture, with host splicing biomarkers.

RIH-owned deep RNA platform + NIGMS R35 + Brown RNA Center—physician-founder spinout before national blood-RNA Dx scale-up.

Patents: 4Stage: clinical translational ldt
US20220340972A1US20250034234A1EP4599084A1CN120344677AR35GM142638PMID 41697057
Open dossier
Tier APatent gapgap_levine_pediatric_sepsis
Wearable pediatric sepsis ML (Levine / Garbern)

Wearable ML for earlier pediatric sepsis recognition—validated in Bangladesh ICU cohort.

FIC R33TW012211 → US SaMD path; pairs with RIH RNA Dx stack.

Patents: —Stage: preclinical grant
R33TW012211R01DK116163D43TW012768PMID 39475844PMID 41252746
Open dossier
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.